Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer
Interventions: BIOLOGICAL: trastuzumab|DRUG: ixabepilone|OTHER: laboratory biomarker analysis
Sponsor: National Cancer Institute (NCI)